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Abstract This study’s aim was to assess neurodevelop-
mental and growth outcome until the age of 4 years of
premature infants placed on early nCPAP, in the setting of
the neonatal intensive care unit (NICU) and follow-up
program of the Division of Neonatology of the Department
of Pediatrics of the University Hospital, Lausanne, Switzer-
land. All consecutive inborn infants weighing <1500 g or
<32 weeks of gestational age admitted to the NICU during
two periods of 12 months—7.1996–6.1997 and 7.1998–
6.1999—were compared before and after the systematic
application of early nCPAP. Of 172 infants admitted to the
NICU, 150 (87%) survived. 126 (84%) were tested at 6
months’ corrected age, 121 (81%) at 18 months’ corrected
age, and 117 (78%) at the age of 4 years. Detailed perinatal
data were collected. Follow-up included neurological
examination, developmental testing and measurement of
growth parameters. Statistical analyses were performed.
Early application of nCPAP and avoidance of mechanical
ventilation showed no adverse effects on neurodevelopment
and growth. A significantly higher developmental quotient
was found in the nCPAP group at 18 months’ corrected age.
Several trends were also noted in the nCPAP group with a
decrease of intraventricular hemorrhage and in “abnormal
neurodevelopment” at 6 months corrected age, a bigger
head circumference at all different tested ages and a greater
height at 6 and 18 months corrected ages. In conclusion,
our study of developmental outcome documents the
absence of any harmful effect of early application of
nCPAP to treat respiratory failure in very low birthweight
infants.
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Abbreviations
nCPAP nasal continuous positive airway pressure
VLBW very low birth weight
DQ developmental quotient
GII general intellectual index
NBRS neurobiological risk score
IVH intraventricular hemorrhage
PVL periventricular leukomalacia
ROP retinopathy of prematurity
AER auditory evoked responses
DQ developmental quotient
GII general intellectual index
Introduction
Early nasal continuous positive airway pressure (nCPAP)
use for premature infants with respiratory distress of
various origins has recently been widely introduced in
neonatal intensive care. It has been shown to lower the
intubation rate and shorten O2 therapy without altering
neonatal mortality and morbidity [1, 7, 14, 21, 28]. A
decreased incidence of bronchopulmonary dysplasia has
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been described by several authors [2, 25], but not by others
[14]. Another area of available information concerns the
short-term neurodevelopmental outcomes, such as the
incidence of severe (grade 3–4) intraventricular hemor-
rhage, periventricular leukomalacia or severe (stage 3–4)
retinopathy of prematurity, which appeared unchanged by
most authors [7, 11, 12]. There is also information about
short-term parameters of growth, such as increased mean
weight, a trend towards increased mean length and head
circumference at 36 weeks corrected gestational age [5, 28]
and shortened time to reach full oral feeds [7].
Several authors [1, 8, 28, 31, 35] stressed the lack of
information regarding consistent neurodevelopmental and
growth outcome of neonates placed preferentially on
nCPAP. Indeed, until very recently, no follow-up studies
were available on the long-term neurodevelopment and
growth of premature infants with early application of
nCPAP. One recent descriptive study [19] found similar
outcome as those described in the literature concerning
preterm babies treated with mechanical ventilation, but did
not directly compare these two populations.
Our study aimed at assessing the effects of early
application of nCPAP on outcome until the age of 4 years
(preschool age), with a detailed collection of neonatal,
ventilatory, neurodevelopmental and growth data. Our
target population was defined as infants with a birthweight
<1500 g (very low birthweight infants, VLBW) or with a
gestational age <32 weeks, who were placed preferentially
and very shortly after birth on nCPAP. This group was
compared to a historical control group of infants placed
preferentially on other modes of respiratory support.
Subjects and methods
All consecutive inborn infants weighing <1500 g or born at
<32 weeks of gestational age, admitted to the Neonatal
Intensive Care Unit (NICU) of the Division of Neonatology
of the Department of Pediatrics of the University Hospital,
Lausanne, Switzerland, during two separate periods of 12
months, were compared. Patients born between July 1,
1996 and June 30, 1997, before the introduction of early
nCPAP, represented the control group, and were used as
historical controls. Patients born between July 1, 1998 and
June 30, 1999, following the systematic introduction of
early nCPAP application to treat respiratory distress,
represented the nCPAP group (study group).
The major difference in management between these two
study periods was the introduction of preferential use of
nCPAP in the study group. In the first period, a standard
ventilation approach had been followed, including the
initial use of either oxyhood, conventional mechanical
ventilation or high-frequency oscillatory ventilation for
infants with moderate or severe respiratory distress. In the
second period, standard policy in the NICU promoted the
routine use of nCPAP in all infants experiencing respiratory
distress of various origins. Nasal CPAP was applied via
nasal cannulae “Infant Flow” at a pressure of 5 cm H2O
within 10 to 30 minutes of birth. Infants with marked
retractions on nCPAP, PaO2<50 mmHg under FiO2 0.8–
1.0, persisting PaCO2>65 mmHg, severe or frequent apnea
with bradycardia on nCPAP or metabolic acidosis (base
excess <−10 mmol/l) were considered to be unsuccessfully
managed on nCPAP and treated with mechanical ventila-
tion. Preterm infants with no respiratory distress at birth
were not placed on nCPAP. No other major changes in
technologies or in nutrition protocols were introduced in the
neonatal intensive care unit during the two periods.
The control group represented 102 children and the
nCPAP group 87. Nine children in the control group and
eight in the nCPAP group were excluded. Of these 17
excluded patients, 12 presented genetic syndromes, major
congenital malformation or congenital cerebral infection,
four had been immediately transferred to another hospital
because of lack of space, and medical records lacked for
one patient. Eleven patients died in each group, 12% (11/93)
in the control group and 14% (11/79) in the nCPAP group,
respectively. The surviving infants (i.e. 82 (88%) in the
control group and 68 (86%) in the nCPAP group) were
eligible for our prospective follow-up program, based on
our birthweight or gestational age cut-offs for follow-up
(<1500 g and/or <32 weeks of gestational age). Written and
oral information were given to parents about the use of the
collected data concerning their children; the different
testing ages were corrected ages of 6 months and 18
months, and the age of 4 years. Our follow-up program has
been approved by the local ethics committee. In the control
group, 65 (79%) infants attended somatic, neurological and
developmental examinations at corrected age of about 6
months, 60 (73%) at the corrected age of about 18 months
and 57 (70%) at the age of about 4 years; respectively, 61
(90%), 61 (90%) and 60 (88%) in the nCPAP group.
Detailed perinatal and neonatal data (obstetrical risk
factors, birth data, major neonatal complications, therapies),
demographic and social data were retrospectively collected
until infants were discharged from the hospital. Gestational
age was defined as the best obstetrical estimate (taking into
account last menstrual period and/or ultrasound examina-
tion). Neurobiological risk score (NBRS) was calculated
according to Brazy et al. [4]. Socio-economic status was
calculated according to Largo et al. [23]. Clinical infection
(antibiotic use for >72 hours, or change of antibiotic
treatment during therapy, or positive culture), thrombocy-
topenia (thrombocytes <100×109/L), hypomagnesaemia
(total magnesium <0.7 mmol/L), and hypothermia (axillary
temperature <36°C) were also noted. Criteria for the
474 Eur J Pediatr (2007) 166:473–483
diagnosis of clinical chorioamnionitis included a patholog-
ical placenta or at least two of the following conditions (or
only one if associated with an antibiotic treatment):
maternal temperature >38°C on two occasions, maternal
CRP >20 mg/L, maternal leukocytosis (>20×109/L white
blood cells), or positive bacterial culture of amniotic fluid
obtained by amniocentesis. Duration of the different types
of respiratory support (nCPAP, mechanical ventilation,
oxyhood, and high-frequency oscillatory ventilation) was
precisely collected. Intubation rate and incidence of
pneumothorax were noted. Chronic lung disease was
considered if infants had either supplemental O2 require-
ments ≥28 days, or beyond 36 weeks [3, 35]. Therapies
including sedation and pressor support were compared
between the groups.
Short-term outcome included results of ultrasonographic
examination of the brain [10, 29], retinopathy of prematu-
rity (ROP) screening [6] and auditory evoked responses
(AER) [30]. Infants were evaluated at follow-up with a
medical history, a physical examination, a standard neuro-
logical examination and developmental testing. Develop-
ment was tested routinely by using at 6 and 18 months of
corrected age the Griffiths’ Developmental Scales with
calculation of a “developmental quotient” (DQ) [15], and
mean and standard-deviations were those defined in the
revised version of the Griffiths scales [20]. At the age of 4
years the McCarthy developmental scales with calculation
of a “general intellectual index” (GII) [27] was used.
Certified testers who performed the neurological and
developmental examinations were not implicated in the
analyses of this study. Major impairments included con-
ditions that almost inevitably had a major effect on the
child’s life such as cerebral palsy, severe visual impairment,
neurosensory hearing loss, mental retardation, epilepsy and
severe psychological disorder, as defined by Fawer et al.
[13]. Neuropsychological anomalies involved less severe
organic conditions including neuromotor signs, minor
visual impairment, minor hearing loss, language disorder
and behavior disorder, as defined by Fawer et al. [13].
Patients were classified as “normal” if their developmental
testing scores were less than one standard-deviation below
average, as “mild retardation” if scores were between one
and two standard-deviations below average, and as “severe
retardation” if scores were more than two standard-devia-
tions below average [15, 20, 27]. Patients were classified as
having an “abnormal neurodevelopment” if they had at
least one minor neurological abnormality or if their
developmental testing scores were more than one stan-
dard-deviation below average. Weight, height and head
circumference measured at the different testing ages were
expressed in percentiles derived by relating the measures to
the infants’ corrected age, according to the Swiss national
growth curves [22].
Differences in neonatal data and neurodevelopmental
outcome between the groups were assessed in an univariate
approach by the nonparametric Wilcoxon rank-sum (Mann-
Whitney) test for continuous values or Fisher’s exact test
for categorical data.
For research questions (related to the effects of nCPAP)
the p value was set at 0.001 applying a Bonferroni
correction for the 50 tests that were performed.
In order to control the plausible effects of the neonatal
variables that were statistically different between the two
groups on outcome, and to determine the exact influence of
nCPAP, all comparisons at the different ages were adjusted
for these variables. Baseline comparisons of the two
treatment groups was set at p<0.01 to determine the
neonatal variables for which an adjustment was warranted
in later comparisons. The level of 0.01 was chosen to be
sure to include all variables that might be different between
the two groups and then have a plausible impact.
Furthermore, in order to control the effects of gestational
age and intrauterine growth retardation, considered impor-
tant determinants of outcome, we performed a complemen-
tary analysis. Using children in the two groups who were
tested at the different ages, a matched pair analysis was
performed using gestational age (±2 days) and small for
gestational age status as matching criteria, choosing
(arbitrarily) the first born match when several were
available.
All calculations and tests were performed using the
statistical software package Stata, Release 8.2 (Stata Corp.,
College Station, TX).
Results
The main neonatal characteristics of our population are
described in Table 1. The two groups were comparable
regarding most perinatal and neonatal data, except gesta-
tional age, clinical infection, thrombocytopenia, hypomag-
nesaemia, chorioamnionitis and hypothermia. Of note, there
was no statistical difference in birth weight, sex distribu-
tion, socio-economic status, or total hospital stay. There
was also no statistical difference in neurobiological risk
score. The survival rate in infants weighing <1500 g or
born at <32 weeks gestational age was 88% (n=82) in the
control group and 86% (n=68) in the nCPAP group. The
mortality rates of the control group and the nCPAP group
were 12% (11/93) and 14% (11/79), respectively, and were
not statistically different. This is in general accordance with
what has been previously described in the literature [26],
describing a mean mortality rate in VLBW of 8% with a
range between 3 and 14%. Among the twenty-two deceased
patients (13%), 7 died during the first day (extreme
prematurity, one in the control group and six in the nCPAP
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group), 12 died between the second day and the end of the
first month of life (infectious or neurological complications
of prematurity, ten in the control group and four in the
nCPAP group), and one in the nCPAP group died at the
postnatal age of 4 months (child abuse after discharge
home). The rate of intubation, the duration of mechanical
ventilation and the use of morphine and catecholamines are
significantly reduced in the group with preferential use of
nCPAP compared with the control group. Pneumothorax
was more frequent in infants with early use of nCPAP, but
this was not statistically significant. It is important to note
that all infants except one diagnosed with pneumothorax in
the nCPAP group received mechanical ventilation. The rate
of chronic lung disease is not different and is rather low in
both groups.
Infants who were lost to follow-up did not differ from
the studied groups concerning their perinatal and neonatal
assessment, and their neurobiological risk score.
Table 1 Neonatal data
Control group, n=93 nCPAP group, n=79 p*
Gestational age, weeks [mean±SD] 30.1±2.7 28.8±2.5 0
Birth weight
grams [mean±SD] 1180.1±342.8 1120.8±309.2 0.3
patients<1500 g [n (%)] 77 (82.8) 68 (86.1) 0.7
small for gestational age † [n(%)] 36 (38.7) 18 (22.8) 0.03
Sex [n (%)] 0.4
male gender 48 (51.6) 44 (55.7)
female gender 45 (48.4) 35 (44.3)
Mortality rate [n (%)] 11 (11.8) 11 (13.9)
Neurobiological risk score (NBRS) ‡ [mean±SD] 10.5±6.4 10.1±5.9 0.8
Socio-economic status § [mean±SD] 7.1±2.4 7.2±2.8 0.9
Patent ductus arteriosus [n (%)] 37 (39.8) 30 (38.0) 0.9
Indomethacin [n (%)] 18 (19.4) 19 (24.1) 0.5
Ligation of patent ductus arteriosus [n (%)] 2 (2.2) 2 (2.5) 1.0
Clinical infection [n (%)] 54 (58.1) 70 (88.6) <0.0005
Necrotizing enterocolitis [n (%)] 12 (12.9) 7 (8.9) 0.5
Chorioamnionitis [n (%)] 16 (17.2) 28 (35.4) 0.01
Thrombocytopenia [n (%)] 48 (51.6) 19 (24.1) <0.0005
Hypomagnesaemia [n (%)] 27 (29.0) 8 (10.1) 0
Hypothermia [n (%)] 49 (52.7) 58 (73.4) 0.01
Total hospital stay, days [mean±SD] 53.6±34.7 58.9±41.4 0.1
Modes of respiratory support [n (%)] <0.0005
Infants receiving no respiratory support 7 (7.5) 10 (12.7)
Infants receiving nCPAP only 1 (1.1) 38 (48.1)
Infants receiving nCPAP and other modes of respiratory support 38 (40.9) 25 (31.7)
Infants receiving other modes of respiratory support 47 (50.5) 6 (7.6)
Intubation rate [n (%)] 64 (68.8) 27 (34.2) <0.0005
Duration of respiratory support, days [mean±SD]
Nasal continuous positive airway pressure (nCPAP) 3.2±8.9 17.7±19.9 <0.0005
Mechanical ventilation 2.6±4.1 1.3±3.3 <0.0005
Oxyhood 3.0±8.3 0.1±0.4 <0.0005
High-frequency oscillatory ventilation 1.0±3.1 0.3±1.2 0.002
Oxygen supplementation 8.9±16.2 5.9±11.8 0.01
Pneumothorax [n (%)] 2 (2.2) 9 (11.4) 0.02
Chronic lung disease [n (%)], defined in infants receiving: 7 (7.5) 4 (5.1) 1.0
O2 supplementation beyond 28 days 7 (7.5) 4 (5.1)
O2 supplementation beyond corrected age of 36 weeks 2 (2.2) 0 (0.0)
Morphine [n (%)] 65 (69.9) 27 (34.2) <0.0005
Catecholamines [n (%)] 49 (52.6) 19 (24.1) <0.0005
* For baseline comparisons, p<0.01 was used to determine the variables that were different between the two groups, and for which adjustment will
be performed
† Small for gestational age was defined by weight at birth < 10th percentile for gestational age
‡ Neurobiological risk score (NBRS), adapted from Brazy et al. [4]
§ Socio-economic status, according to Largo et al. [23]
|| Others modes of respiratory support included mechanical ventilation, oxyhood and high-frequency oscillatory ventilation
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Table 2 includes the short-term outcome measurements
(intraventricular hemorrhage, periventricular leukomalacia,
retinopathy of prematurity, and auditory evoked responses)
and compares the findings of both groups including either
the entire group or the findings restricted to survivors
included in the long-term follow-up. There was no
statistical difference between the two groups on the
incidence of intraventricular hemorrhage and periventricu-
lar leukomalacia. Numbers of retinopathy of prematurity
stages 3 or above and abnormal auditory evoked response
were similar between the two groups.
Tables 3, 4 and 5 present the results of the neuro-
developmental examination at 6 months, 18 months, and at
4 years of age, respectively. The only significant difference
was a higher mean developmental quotient restricted to the
18 month examination in the patient group with preferential
use of nCPAP (p=0.0002). The two modes of ventilatory
approach had no statistical influence on the other neuro-
developmental data.
Figure 1 presents the evolution of growth parameters at
the different ages. The only significant difference was a
taller height equally restricted to the 18-month examination
in the nCPAP group (p=0.001). The other comparisons did
not show any statistical difference.
Perinatal variables that were statistically different be-
tween the two groups were gestational age, clinical
infection, thrombocytopenia, hypomagnesaemia, chorioam-
nionitis and hypothermia, as detailed in Table 1. Because
Table 2 Short-term outcome
Control
group
all patients,
n=93
nCPAP
group
all patients,
n=79
p* (adjusted p) Control
group
survivors
nCPAP
group
survivors
p* (adjusted p) Matched
pair
analysis
p*
Intraventricular hemorrhage (IVH)
Number of examined infants n=88 n=78 n=78 n=68
Grades † [n (%)] 0.4 (0.03) 0.2 (0.09) 0.1
Grade 0 64 (72.7) 60 (76.9) 61 (78.2) 56 (82.4)
Grade 1 7 (8.0) 9 (11.5) 6 (7.7) 9 (13.2)
Grade 2 9 (10.2) 3 (3.9) 9 (11.5) 2 (2.9)
Grade 3 2 (2.3) 3 (3.9) 1 (1.3) 1 (1.5)
Grade 4 6 (6.8) 3 (3.9) 1 (1.3) 0 (0.0)
Periventricular leukomalacia (PVL)
Number of examined infants n=88 n=78 n=78 n=68
Grades ‡ [n (%)] 0.8 (0.8) 0.8 (0.7) 0.7
Grade 0 76 (86.4) 68 (87.2) 67 (85.9) 60 (88.2)
Grade 1 8 (9.1) 9 (11.5) 7 (9.0) 7 (10.3)
Grade 2 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Grade 3 3 (3.4) 1 (1.3) 3 (3.9) 1 (1.5)
Grade 4 1 (1.1) 0 (0.0) 1 (1.3) 0 (0.0)
Retinopathy of prematurity (ROP)
Number of examined infants n=67 n=61 n=67 n=60
Stages § [n (%)] 1.0 1.0
Stage 3 or above 2 (3.0) 1 (1.6) 2 (3.0) 1 (1.7)
Auditory evoked responses (AER)
Number of examined infants n=43 n=41 n=43 n=40
Classification || [n (%)] 0.02 (0.8) 0.02 (0.9) 0.03
0 = normal 29 (67.4) 30 (73.2) 29 (67.4) 30 (75.0)
1 = first recording abnormal
(second recording normal)
6 (14.0) 11 (26.8) 6 (14.0) 10 (25.0)
2 = second recording abnormal
(first recording normal)
3 (7.0) 0 (0.0) 3 (7.0) 0 (0.0)
3 = first and second recordings abnormal 5 (11.6) 0 (0.0) 5 (11.6) 0 (0.0)
* For research questions relating to the effects of nCPAP, p (and adjusted p)<0.001 was used to determine significant effects. Adjusted
p represented the p values of analyses performed again after adjusting for the variables that were statistically different between the
two groups
‡ Classification of PVL, according to de Vries et al. [10]
§ Classification of ROP, according to the International Committee for the Classification of the late Stages of Retinopathy of Prematurity [6]
|| Classification of AER, according to Pasman et al. [30]
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Table 4 Neurodevelopmental outcome at 18-month of corrected age
Control
group
n=60 †
nCPAP
group
n=61 †
p* (adjusted p) Matched pair
analysis, p*
Age at testing, months [mean±SD] 18.9±2.4 18.9±1.4 0.4
Neurodevelopmental outcome
Developmental quotient (DQ) †
Developmental quotient (DQ) [mean±SD] 104.0±11.2 111.2±10.4 0.0002 (0.006) <0.0001
Ranges 0.5 (0.3) 1.0
1 = normal=>94.2 [n (%)] 59 (98.3) 59 (96.7)
2 = mild retardation=82.1–94.2 [n (%)] 0 (0.0) 2 (3.3)
3 = severe retardation=<82.1 [n (%)] 1 (1.7) 0 (0.0)
Neurological status 0.6 (1.0) 0.3
0 = normal [n (%)] 50 (83.3) 54 (88.5)
1 = 1 neuropsychological anomaly [n (%)] 5 (8.3) 4 (6.6)
2 = >1 neuropsychological anomalies [n (%)] 2 (3.3) 0 (0.0)
3 = 1 major impairment [n (%)] 2 (3.3) 2 (3.3)
4 = 1 major impairment + ≥1 neuropsychological anomalies [n (%)] 0 (0.0) 1 (1.6)
5 = >1 major impairments [n (%)] 0 (0.0) 0 (0.0)
6 = ≥1 major impairments + ≥ 1 neuropsychological anomalies [n (%)] 1 (1.7) 0 (0.0)
“Abnormal neurodevelopment” ‡ 13 (21.7) 8 (13.1) 0.2 (0.5) 0.1
* For research questions relating to the effects of nCPAP, p (and adjusted p)<0.001 was used to determine significant effects. Adjusted
p represented the p values of analyses performed again after adjusting for the variables that were statistically different between the two
groups
† Developmental quotient was calculated using the Griffiths’ developmental scales [15]
‡ An “abnormal neurodevelopment” was defined by a developmental quotient more than 1 standard-deviation below average (less than 94.2)
[15, 20] or a pathological neurological status
Table 3 Neurodevelopmental outcome at 6-month of corrected age
Control
group,
n=65†
nCPAP
group,
n=61†
p* (adjusted p) Matched pair
analysis, p*
Age at testing, months [mean±SD] 7.0±1.5 6.6±1.3 0.2
Neurodevelopmental outcome
Developmental quotient (DQ) †
Developmental quotient (DQ) [mean±SD] 98.8±14.0 101.9±9.8 0.1 (0.6) 0.4
Ranges 0.3 (0.1) 1.0
1 = normal=>85.6 [n (%)] 57 (87.7) 58 (95.1)
2 = mild retardation=74–85.6 [n (%)] 6 (9.2) 3 (4.9)
3 = severe retardation=<74 [n (%)] 2 (3.1) 0 (0.0)
Neurological status 1.0 (0.8) 0.2
0 = normal [n (%)] 45 (69.2) 45 (73.8)
1 = 1 neuropsychological anomaly [n (%)] 14 (21.5) 13 (21.3)
2 = >1 neuropsychological anomalies [n (%)] 3 (4.6) 1 (1.6)
3 = 1 major impairment [n (%)] 1 (1.5) 1 (1.6)
4 = 1 major impairment + ≥1 neuropsychological anomalies [n (%)] 1 (1.5) 1 (1.6)
5 = >1 major impairments [n (%)] 0 (0.0) 0 (0.0)
6 = ≥1 major impairments + ≥1 neuropsychological anomalies [n (%)] 1 (1.5) 0 (0.0)
“Abnormal neurodevelopment” ‡ 24 (36.9) 16 (26.2) 0.2 (0.09) 0.09
* For research questions relating to the effects of nCPAP, p (and adjusted p)<0.001 was used to determine significant effects. Adjusted
p represented the p values of analyses performed again after adjusting for the variables that were statistically different between the two
groups
† Developmental quotient was calculated using the Griffiths’ developmental scales [15]
‡ An “abnormal neurodevelopment” was defined by a developmental quotient more than 1 standard-deviation below average (less than 85.6)
[15, 20] or a pathological neurological status
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these significant variables might have a plausible relationship
to neurological and growth outcomes, analyses were per-
formed again after adjusting for these variables and the results
were similar. Mean developmental quotient at 18 months
examination in the patient group with preferential use of
nCPAP remained higher (p=0.006). Height was taller at 18
months of corrected age, but the difference was not
statistically significant (p=0.11). Of note, after adjusting for
the variables mentioned above, infants with preferential use
of nCPAP tended to have a less severe grade of intraven-
tricular hemorrhage (p=0.027) with a risk divided by two;
however, this finding did not reach statistical significance. In
the same way, head circumference tended to be bigger in
infants with preferential use of nCPAP at the different tested
ages, but this did not reach statistical significance (respec-
tively, p=0.039 at 6 months of corrected age, p=0.030 at 18
months of corrected age, and p=0.12 at the age of 4 years).
Smaller mean gestational age was observed in the
nCPAP group (28.8 weeks versus 30.1 weeks for the
control group, p=0.0007), and intrauterine growth retarda-
tion (weight at birth <10th percentile for gestational age)
tended to be more frequent in the control group (39%
versus 23% in the nCPAP group, p=0.033). Considering
that these factors are important determinants of outcome we
performed an additional paired comparison, as outlined in
the methods section. Thirty-eight pairs of children were
thus formed and the results reinforced the trends noted in
the previous analyses. The value of DQ at 18 months was
significantly higher in the nCPAP group (p<0.0001). Height
was significantly taller in the nCPAP group at 6 months
(p<0.0005) and at 18 months (p<0.0001). A trend towards a
diminution in the incidence of intracranial hemorrhage in
the nCPAP group was noted (p=0.1, with a risk divided by
two, which may be clinically relevant). Head circumference
was larger and significantly so at all three postnatal ages in
the group with preferential use of nCPAP (p<0.001 at 6
months, p<0.008 at 18 months and p<0.009 at the age of 4
years).
Discussion
The management of respiratory distress in premature
newborn infants using preferentially early nasal nCPAP
rather than conventional ventilation has gained wider
acceptance over the last decade. It has been shown to
decrease respiratory morbidity [2, 7–9, 11, 14, 21, 28]. Its
influence on other neonatal outcome [7, 11, 12] is debated.
Controlled data on long-term neurodevelopmental outcome
and somatic growth are not yet available.
The results of our study confirm the favorable influence
of nCPAP on early neonatal outcome measurements, and
document the safety of this approach in terms of long-term
neurodevelopmental outcome and somatic growth. Indeed,
follow-up data up to 4 years of age of newborn infants
<1500 g and/or <32 weeks gestation treated either with
Table 5 Neurodevelopmental outcome at age of 4 years
Control
group, n=57†
nCPAP
group, n=60 †
p* (adjusted p) Matched pair
analysis, p*
Age at testing, months [mean±SD] 48.9±5.4 47.2±3.3 0.04
Neurodevelopmental outcome
General intellectual index (GII) †
General intellectual index (GII) [mean±SD] 101.6±17.1 99.7±17.7 0.2 (0.6) 0.8
Ranges 0.4 (1.0) 1.0
1 = normal=>84 [n (%)] 46 (80.7) 47 (78.3)
2 = mild retardation=68–84 [n (%)] 8 (14.0) 12 (20.0)
3 = severe retardation=<68 [n (%)] 3 (5.3) 1 (1.7)
Neurological status 0.08 (0.7) 0.6
0 = normal [n (%)] 23 (40.4) 26 (43.3)
1 = 1 neuropsychological anomaly [n (%)] 21 (36.8) 24 (40.0)
2 = >1 neuropsychological anomalies [n (%)] 8 (14.0) 7 (11.7)
3 = 1 major impairment [n (%)] 0 (0.0) 3 (5.0)
4 = 1 major impairment + ≥1 neuropsychological anomalies [n (%)] 5 (8.8) 0 (0.0)
5 = >1 major impairments [n (%)] 0 (0.0) 0 (0.0)
6 = ≥1 major impairments + ≥ 1 neuropsychological anomalies [n (%)] 0 (0.0) 0 (0.0)
“Abnormal neurodevelopment” ‡ 34 (59.7) 36 (60.0) 1.0 (0.9) 0.5
* For research questions relating to the effects of nCPAP, p (and adjusted p)<0.001 was used to determine significant effects. Adjusted p represented
the p values of analyses performed again after adjusting for the variables that were statistically different between the two groups
† General Intellectual Index was calculated using the McCarthy’s developmental scales [27]
‡ An “abnormal neurodevelopment” was defined by a general intellectual index more than 1 standard-deviation below average (less than 84) [27]
or a pathological neurological status
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early nCPAP or conventional ventilation showed no
significant difference. On the contrary, the nCPAP group
showed several trends that seemed to suggest better
outcome.
The incidence of intracranial hemorrhage documented by
neonatal ultrasound was diminished in the nCPAP group
(12% versus 29% in the control group, adjusted p=0.027).
Although this result does not reach statistical significance,
the risk is diminished by more than half (odd ratio=0.41)
and this might well be clinically relevant. Of note, maximal
PCO2 values were equal between the two groups (56 versus
55 mmHg, p=0.059), and the prevalence of clinical patent
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Fig. 1 Growth (weight, length and head circumference) at birth, at 6
and 18 months of corrected age, and at 4 years of age. * For research
questions related to the effects of nCPAP, p (and adjusted p)<0.001
was used to determine significant effects. Adjusted p represented the p
values of analyses performed again after adjusting for the variables
that were statistically different between the two groups
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ductus arteriosus was not different. These combined
findings could suggest a favorable influence of nCPAP on
cerebral hemodynamics. This could happen via a mecha-
nism including reduced intrathoracic pressure swings and
more physiological venous return and cardiac output, the
disturbances of which have been implicated as a possible
mechanism for intracranial bleeding [7]. In contrast, the
incidence of periventricular leukomalacia was unchanged
(adjusted p=0.84). Of note, the incidence of chorioamni-
onitis, a known risk factor of periventricular leukomalacia,
tended to be more frequent in the nCPAP group, and might
then have blurred some positive effects of nCPAP on the
incidence of periventricular leukomalacia. However this
item was included in the variables that were statistically
different between the two groups and the incidence of
periventricular leukomalacia was not different between the
two groups in the analyses after adjusting for these
variables. Moreover, physiopathological mechanisms un-
derlying periventricular leukomalacia seemed to be differ-
ent from those of intracranial hemorrhage, and might
therefore be less subject to the mode of ventilatory support.
It is important to note that all infants diagnosed with
IVH 3-4, PVL 2-4 or ROP 3-4 received mechanical
ventilation during the first week of life (duration between
one day and more than one week).
With regards to long-term outcome, the use of nCPAP
appears to diminish the risk of having an abnormal
neurodevelopment at 6 months of age (22% versus 39%
in the control group, adjusted p=0.093) and to diminish as
well the risk of having a DQ (developmental quotient)
below one standard deviation at 6 months (2% versus 8% in
the control group, adjusted p=0.12). This effect on the DQ
seems to decrease with advancing age but is still significant
at 18 months with values of 110.6 versus 104.8 after
adjustment (p=0.006), and disappears at the age of 4 years.
Some of the neonatal effects of nCPAP on neurodevelop-
ment might be blurred with advancing age (intervening
diseases, rehospitalization rate, stimulating environment,
resort to special education resources), explaining why there
is no more difference at the age of 4 years.
When considering somatic growth, nCPAP use was not
associated with any difference in weight whereas height
tended to be taller at 6 months (p=0.04, adjusted p=0.084)
and at 18 months as well (p=0.001, adjusted p=0.11). Head
circumference tended to be larger at 6 months, 18 months
and at the age of 4 years (respectively, p=0.086/adjusted
p=0.039 at 6 months corrected age; p=0.24/adjusted
p=0.030 at 18 months of corrected age; and p=0.03/
adjusted p=0.12 at age of 4 years). Considering the link
between head growth and future cognitive function [16, 17,
33], it seems important that this potential effect on head
circumference be further evaluated since it could be an
argument in favor of nCPAP use.
In this study, we have collected a large number of
neonatal factors known to potentially influence neuro-
development and growth. We determined for each infant
its NBRS [4]; there was no statistical difference in NBRS
between the 2 groups, confirming that the infants in both
groups were comparably sick and equally at risk. Various
perinatal variables were statistically different between the
two groups (gestational age, clinical infection, thrombocy-
topenia, hypomagnesaemia, chorioamnionitis and hypother-
mia) and analyses were adjusted for these variables.
Considering all neonatal factors that were different
between the two groups, and which motivated the adjust-
ment, it is important to refer to gestational age. Gestational
age was significantly lower in the nCPAP group (28.8
versus 30.1 weeks gestation in the control group,
p=0.0007), and could have had a disproportionately
stronger negative influence on neurodevelopment [18, 26].
The difference in gestational age between the groups could
have therefore canceled some positive effects of nCPAP in
comparison to conventional ventilation. The same consid-
eration was given to the association of fetal growth
retardation (although not significantly different between
the groups, p=0.36) [24, 32, 34]. For these reasons we
performed additional matched pair analyses (matching
individuals according to their gestational age and the
presence or absence of fetal growth retardation). The results
of these pair analyses have to be considered in view of the
reduction in the number of pairs matched (38 pairs) but can
be taken to confirm the results of our previous analyses.
This study describes a fairly recent population of
consecutively born premature infants who have been
managed in a modern neonatal ICU environment during a
relatively short period of time (3 years). The design of the
study was a retrospective “before-after trial” with a limited
sample size, and presented the major limitation of not being
a randomized study. It is important to note that neonatal and
neurodevelopmental data were collected separately, in a
coded and blinded fashion. Certified testers who performed
the neurological and developmental examinations were not
implicated in the analyses of this study, and were blinded to
the type of respiratory support these infants received.
Another limitation is the difference in follow-up ratio
between the two study periods, with less drop-outs in the
group with preferential use of nCPAP. However, infants
who were lost to follow-up did not differ from the studied
groups concerning their perinatal and neonatal assessment
and their neurobiological risk score. Of the 33 infants lost
to follow-up, no information was available for 16 infants
who moved away from the test center. Some neuro-
developmental information was obtained with a structured
phone interview or a follow-up in another test center for 17
infants (12 in the control group and 5 in the nCPAP group).
In the control group, four children were described as
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normal, four with a single neuropsychological anomaly,
three with several, and one with cerebral palsy (this infant
was seen at 6 and 18 months of corrected age, and the
diagnosis was already reported at this time). In the nCPAP
group, four were described as normal, and one with a single
neuropsychological anomaly.
In summary, our study documents the safety of early
nasal CPAP treatment on long-term outcome of infants
<1500 g or <32 weeks of gestational age. It thus provides
an additional argument in favor of the systematic use of
nCPAP as an initial approach in premature infants with
respiratory distress. Prospective randomized trials and long-
term follow-up studies are needed to confirm these
findings.
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